Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
Vietnam’s pharmaceutical market is expected to have a year of optimism after experiencing a multicoloured gamut in 2024.
Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...
Global Biopharmaceuticals Market Depth of Insights Ethnography’s Contribution to Consumer Behavior
Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...
Vietnam will hold talks with foreign partners this month about projects to develop its first two nuclear power plants, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback